News

The collaboration will explore the novel signaling pathways targeted by two of Jerini Ophthalmic’s leading drug candidates, JSM 6427, an integrin antagonist, and JPE 1375, an inhibitor of

The company said that AVN944 biomarkers show a dose-dependent increase in activity including, binding to the target enzyme IMPDH, depletion of GTP pools in blast cells and gene

The median overall survival advantage for Vidaza-treated patients compared to conventional care regimens (CCR) treated patients in this clinical trial in myelodysplastic syndromes (MDS) was 9.4 months (24.4

To date, 33 patients have been enrolled in this ongoing open-label Phase II study of refractory/relapsed classical Hodgkin lymphoma (HL). The majority of these patients have disease that

Additionally, romiplostim-treated patients taking concurrent immune thrombocytopenic purpura (ITP) medications such as corticosteroids were able to reduce or discontinue these medications. Efficacy and safety data from another pivotal

Revlimid was active with both dose levels of dexamethasone. The best overall response for high-dose dexamethasone (CR/VGPR/PR) was 82% compared to 71% in the low-dose dexamethasone arm, including

The company said that it has changed its corporate name to emphasize its mission to commercialize the mammastatin serum assay and to pursue development of the mammastatin protein

Patients received either two doses of 510 mg of intravenous (IV) ferumoxytol within one week or 200 mg of oral iron daily for three weeks and were followed

Preliminary data from the pilot study suggests repeat administration with Inno-305 is well tolerated and immune response can be elicited following three vaccinations. In the study conducted at